The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries
Oxford University Press, 2005 - Business & Economics - 358 pages
The establishment of the World Trade Organization (WTO) in 1995 brought about significant changes in international economic relations between countries. To comply with the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement of the WTO, India introduced product patentprotection in pharmaceuticals from January 2005. TRIPS has generated a huge controversy in India and abroad. India has emerged as a major source of low-cost, quality drugs for the entire world and thus plays an important role.While there are a large number of pharmaceutical manufacturers in the world, only a handful of multinationals dominate the industry. By using patent rights, multinational companies prevednted developing countries like India from realizing their potential of industrial growth and drug prices wereamong the highest in the world.The book analyses:* the remarkable growth of the Indian pharmaceutical industry since the early 1970s when product patent protection in pharmaceu ticals was abolished* whether the claimed benefits for developing countries, under TRIPS, have materialized* what can be done, if as apprehended, the prices of patent protected drugs rise* whether, and to what extent, developing countries have been able to use the provisions and the flexibilities promised under TRIPSThe volume will be of interest not only to academics but also to policymakers, pharma companies, business analysts, students, NGOs, and others interested in the impact of globalization under WTO.
What people are saying - Write a review
Very interesting and well written book offering a counter intuitive perspective on the impact of TRIPS on India's pharma industry's future. Depicts the efforts and understanding which has gone into the making of this book. Recommend it highly. However, a revised edition incorporating latest development, post TRIPS would be interesting.
Rise and Growth of the Pharmaceutical
Patent Regime and Role of MNCs in
TRIPS and RD for Neglected Diseases
6 other sections not shown